Congenital afibrinogenemia is a rare autosomal recessive disorder characterized by the complete absence of detectable fibrinogen. We previously identified the first causative mutations for this disease, these were homozygous deletions of approximately 11 kb of the fibrinogen alpha chain gene (FGA). Subsequent analyses revealed that the great majority of afibrinogenemia alleles are truncating mutations of FGA, although mutations in all three fibrinogen genes, FGG, FGA and FGB have been identified. In this study, we performed the first prenatal diagnosis for afibrinogenemia. The causative mutation in a
Palestinian family was a novel nonsense mutation in the FGB gene, W467X. Expression of the W467X mutant FGB cDNA in combination with wild-type FGA and FGG cDNAs showed that fibrinogen molecules containing the mutant beta-chain are not secreted into the media. The fetus was found to be heterozygous for the W467X mutation by direct sequencing and by linkage analysis, a result which was confirmed in the new-born by intermediate fibrinogen levels.
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INTRODUCTION
Congenital afibrinogenemia (MIM #202400), characterized by a complete absence of detectable fibrinogen, was originally described in 1920 1 and to date some 150 families with this disorder have been reported 2 with approximately 50% of cases present in consanguineous families 3 . Although functional assays of clot formation are infinitely prolonged in affected individuals, the coagulation defect is surprisingly no more severe than in severe hemophilias A and B 4,5
. Umbilical cord hemorrhage is often the first sign of the disorder; gum bleeding, epistaxis, menorrhagia, gastro-intestinal bleeding and hemarthrosis occur with varying intensity, and spontaneous intracerebral bleeding and splenic rupture can occur throughout life.
Fibrinogen is synthesized in the hepatocyte from three homologous polypeptide chains, A , B and which assemble to form the hexameric structure (A B ) 2 . The three genes coding for fibrinogen gamma (FGG), alpha (FGA) and beta (FGB) are clustered in a region of approximately 50 kb on chromosome 4q28-q31 6 . We previously identified the first causative mutations for this disorder 7 the genetic defect in a non-consanguineous Swiss family was an apparently recurrent deletion of approximately 11 kb of DNA which eliminates the majority of the FGA gene and so leads to a complete absence of functional fibrinogen. Since our identification of the disease locus, numerous causative mutations have been characterized in FGA (the great majority of cases 8, 9 ) but also in FGG and FGB, allowing a precise molecular diagnosis for the patients, as well as prenatal diagnosis for the families concerned. In this study, the first prenatal diagnosis for afibrinogenemia was performed, for a Palestinian family with two affected daughters. 
MATERIALS AND METHODS

Description of Family:
Informed consent was obtained from the adults participating in the study. The parents were a healthy consanguineous Palestinian couple with no history of bleeding tendency.
Their first conception was a miscarriage during the first trimester. The second and third conceptions produced two daughters who were born at term with birth weights of 2.9 and 3 kg, respectively. The bleeding tendency in the two daughters was noted during mid infancy ( between 4-5 months of age) in the form of serious intra-cranial bleeding after non significant trauma. Fibrinogen levels were undetectably low (< 50 mg/dl), establishing the diagnosis of congenital afibrinogenemia. Following diagnosis, treatment consisted of infusions of fresh frozen plasma (FFP) following any significant bleeding, approximately once every 5-6 months. No infusion was required for the last 2 years because of increased parental awareness of accident and trauma prevention. Fibrinogen levels were determined for the parents and were found to be 170 and 150 mg/dl for the mother and the father, respectively.
Mutation screening in family members:
Mutation screening of the FGA, FGG and FGB gene was performed by PCR amplification of all exons and intron-exon junctions followed by sequencing as previously .
Microsatellite analysis:
The FGA i ntron 3 tetranucleotide repeat (FGAi3) was analyzed by PCR amplification with oligonucleotides FGA PCR2.1 (5'CCATAGGTTTTGAACTCACAG3') and FGA PCR2.2 (5'CTTCTCAGATCCTCTGACAC3') followed by denaturing polyacryamide-urea gel electrophoresis according to standard procedures.
Amniocentesis:
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Amniocentesis was performed by the usual procedure at 16 weeks of gestation.
Amniotic fluid cells were cultured and after achieving adequate growth, DNA was prepared and analyzed for the mutation present in the affected daughters.
Expression and analysis of the FGB W467X mutation in COS-7 cells:
The three human fibrinogen cDNAs, FGA, FGB and FGG were obtained by RT-PCR on HepG2 cells and cloned into the pcDNA3.1/V5-His TOPO mammalian expression vector (Invitrogen). The W467X mutation was inserted in the FGB construct using the column (Millipore) before adding reducing or non reducing Laemmli buffer. Cells were lysed in 2x concentrated Laemmli buffer. After boiling at 95°C for 5 minutes, samples were analysed by SDS-PAGE (7.5% or 10%). Western blot analysis was performed using rabbit anti-human fibrinogen antibodies (Dako) at a 1:2500 dilution.
Immunoreactive bands were revealed with an enhanced chemiluminescence kit (ECL;
Amersham Pharmacia Biotech) according to manufacturer's instructions.
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RESULTS AND DISCUSSION
A consanguineous Palestinian couple (first cousins) with two daughters with congenital afibrinogenemia requested a prenatal diagnosis for their ongoing pregnancy ( Figure 1A ).
In the first step, DNA was extracted from fresh EDTA blood samples from parents and affected children for identification of the causative mutation transmitted in this family.
Screening of all the coding regions and exon-intron junctions for FGA ( isoform, exons 1-5) and FGG by PCR and sequencing showed no mutation. Analysis of the FGB gene revealed a previously unreported nonsense mutation in the last exon, exon 8, W467X
(TGG>TAG) (numbered from the first ATG codon according to guidelines for human mutation nomenclature 11, 12 ) which was found in heterozygosity in each of the parents, and in homozygosity in each of the two affected daughters ( Figure 1B ).
Microsatellite analysis of the FGA intron 3 tetranucleotide repeat (FGAi3) was also performed; both parents were found to be heterozygous for the FGAi3 microsatellite marker, while the two affected daughters were homozygous (data not shown).
Mutation analysis was performed on DNA isolated from cultured amniocytes and the fetus was found to be heterozygous for the familial W467X mutation both by sequencing and FGAi3 microsatellite analysis. This result was confirmed in the newborn when the mother gave birth to a healthy baby boy weighing 2.9 kg at birth, and fibrinogen determination revealed a level of 120 mg/dl consistent with heterozygosity for an afibrinogenemia mutation.
The W467X mutation was predicted to lead to the production of a truncated fibrinogen beta chain, with 25 amino acids missing from the C-terminus ( Figure 1C) . Alternatively, the truncated beta polypeptide might be unstable or the mutation might cause a defect in the FGB mRNA, by aberrant splicing (nonsense-associated alternative splicing) or by affecting the stability of the mRNA through nonsense-mediated mRNA decay 13-15 . However, because the W467X mutation lies within the last exon of FGB, these mechanisms are not thought to be activated.
Previous studies in COS-1 cells expressing normal fibrinogen alpha and gamma chains
in combination with beta-chain deletion mutants had led to the conclusion that the Cterminal portion of the beta-chain, notably residues 238-491 (numbering from the initiator methionine), was not essential for fibrinogen assembly and secretion 16 . In order to prove the causative nature of the mutation, W467X mutant and wild-type FGB cDNAs were (Media A and B, lane 3) . These results closely resemble those previously described in COS cells transfected with different combinations of the three normal fibrinogen cDNAs. 17 When cells are transfected with equal amounts of wild-type and mutant FGB cDNAs (and normal FGA and FGG cDNAs), imitating heterozygosity for the W467X mutation, both beta chains are clearly distinguished in the Western blot of cell lysates, with the normal chain being more abundant (Figure 2A, Cells lane 2) . By contrast, in the cell medium only the wild-type beta chain is found ( Fig. 2A, Media lane 2) .
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From .. 8 The data demonstrate that truncation of the last 25 amino acid residues from the fibrinogen beta chain C-terminus does not inhibit hexamer assembly but eliminates its secretion, as previously reported for two missense mutations in FGB exons 7 and 8 identified in afibrinogenemia patients 18 . These results are apparently in contradiction with the experimental observation that fibrinogen beta-chains truncated at amino acid position 238 were able to assemble with alpha and gamma fibrinogen chains and were secreted into the media 16 . However, the assembly and secretion of such a severely truncated polypeptide may not be physiologically relevant.
Interestingly, Homer et al. 19 reported a very similar mutation (Trp440Stop, amino acids numbered without the signal peptide, or W470X according to our nomenclature) which occurs only 3 codons downstream of the W467X mutation. The W470X mutation "fibrinogen Mount Eden" was identified in heterozygosity in a patient following laboratory investigations prior to a liver biopsy for hepatitis C. The patient had reduced fibrinogen levels (0.7 mg/ml) and a prolonged APTT. Other than mild epistaxis and gum bleeding, the patient was asymptomatic. The authors showed that the truncated fibrinogen beta chain was not found in the patient's plasma and suggested that removal of the Cterminal 22 residues does not allow incorporation of the mutant chain into mature fibrinogen hexamers. No fibrinogen inclusion bodies were detected in the liver biopsy, indicating that molecules containing the mutant chains do not accumulate in the patient's hepatocytes. We suggest that the molecular mechanism may be at the level of secretion, as with the W467X mutation we describe. The authors state that the mutation causes hypofibrinogenemia in heterozygosity, however one can consider it an afibrinogenemia mutation since a homozygous individual for this mutation will most certainly have no circulating fibrinogen at all.
In conclusion, the W467X mutation identified in this study, along with the W470X mutation 19 and three missense mutations 18,20 identified in the same region in 
